Pliant Therapeutics
PLRX
151 hedge funds and large institutions have $725M invested in Pliant Therapeutics in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 16 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 32
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
6% more capital invested
Capital invested by funds: $687M → $725M (+$38.1M)
5% more funds holding
Funds holding: 144 → 151 (+7)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1.53% less ownership
Funds ownership: 105.96% → 104.43% (-1.5%)
74% less call options, than puts
Call options by funds: $1.31M | Put options by funds: $4.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$38.8M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$3.75M |
| 3 |
BlackRock
New York
|
+$3.09M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$2.95M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$26.9M |
| 2 |
CC
Casdin Capital
New York
|
-$10.8M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$10.3M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.09M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.95M |
PLRX Hedge Fund Activity: Q3 2024 in Review
151 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2024, worth a combined $725M — up 5.6% from $687M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PLRX positions and 16 closed out — a net gain of 7 holders — while 60 added to existing stakes and 32 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $38.8M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $26.9M sold.
- 151 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2024, up from 144 in Q2 2024.
- Funds reported $725M of Pliant Therapeutics stock for Q3 2024, up 5.6% quarter-over-quarter.
- 23 funds opened new Pliant Therapeutics positions in Q3 2024 and 16 closed out, a net change of +7 holders.
- The largest Pliant Therapeutics buyer in Q3 2024 was Paradigm Biocapital Advisors, an estimated $38.8M added.
- The largest Pliant Therapeutics seller in Q3 2024 was Laurion Capital Management, an estimated $26.9M sold.
Based on aggregated 13F filings for Q3 2024.